IP Library Patent Application 12298265
Patent Application
App. No. 12/298,265

GEMCITABINE COMBINATION THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/298,265
Abstract

The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Claims (10)

1 . A method comprising steps of:

administering to a subject suffering from or susceptible to a cell proliferative disorder, combination therapy of a DAC inhibitor and gemcitabine.

2 . The method of claim 1 wherein the cell proliferative disorder involves a tumor.

3 . The method of claim 2 , wherein the tumor is a Ras-expressing tumor.

4 . The method of claim 2 , wherein the tumor is a pancreatic tumor.

5 . The method of claim 1 , wherein the DAC inhibitor is romidepsin.

6 . The method of claim 1 further comprising administering electrolyte supplementation.

7 . The method of claim 1 , wherein the cell proliferative disorder is cutaneous T-cell lymphoma.

8 . The method of claim 1 , wherein the cell proliferative disorder is peripheral T-cell lymphoma.

9 . The method of claim 1 , wherein the cell proliferative disorder is a hematological malignancy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2012
From: GLOUCESTER PHARMACEUTICALS, INC.
To: CELGENE CORPORATION
Reel/Frame 028020/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2010
From: KEEGAN, MITCHELL
To: GLOUCESTER PHARMACEUTICALS, INC.
Reel/Frame 024383/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2009
From: MCCULLOCH, WILLIAM
To: GLOUCESTER PHARMACEUTICALS, INC.
Reel/Frame 023200/0018 →